Baker McKenzie client Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system disorders (CNS), and the Neuraxpharm Group, a leading European specialty pharmaceutical company focused on CNS therapies, announced the completion of a strategic license agreement for the European rights to leriglitazone, a novel, brain penetrant and selective PPAR gamma agonist.
Under the agreement, Minoryx will receive from Neuraxpharm a significant double-digit upfront payment in addition to milestone payments and development funding totaling up to EUR 258 million in the aggregate. Minoryx will also receive material tiered double-digit royalties.
Led by Corporate Partner Randall Sunberg (Princeton / New York), the Baker McKenzie Madrid team acting on the matter involved for corporate aspects Carlos Martin, for IP Maria Dolores Garayalde and Ruben Cano and for international commercial & trade: Cecilia Pastor.
Clifford Chance has advised the Neuraxpharm Group with partner Guillermo Guardia and associate Aina Gómez.